These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 31573107)

  • 1. MDMA Is Not Ecstasy: The Production of Pharmaceutical Safety through Documents in Clinical Trials.
    Hendy K
    Med Anthropol Q; 2021 Mar; 35(1):5-24. PubMed ID: 31573107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. From ecstasy to MDMA: Recreational drug use, symbolic boundaries, and drug trends.
    Edland-Gryt M; Sandberg S; Pedersen W
    Int J Drug Policy; 2017 Dec; 50():1-8. PubMed ID: 28869878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deaths involving MDMA and the concomitant use of pharmaceutical drugs.
    Pilgrim JL; Gerostamoulos D; Drummer OH
    J Anal Toxicol; 2011 May; 35(4):219-26. PubMed ID: 21513615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MDMA interactions with pharmaceuticals and drugs of abuse.
    Papaseit E; Pérez-Mañá C; Torrens M; Farré A; Poyatos L; Hladun O; Sanvisens A; Muga R; Farré M
    Expert Opin Drug Metab Toxicol; 2020 May; 16(5):357-369. PubMed ID: 32228243
    [No Abstract]   [Full Text] [Related]  

  • 5. Methylenedioxymethamphetamine (MDMA, 'ecstasy') serves as a robust positive reinforcer in a rat runway procedure.
    Wakonigg G; Sturm K; Saria A; Zernig G
    Pharmacology; 2003 Dec; 69(4):180-2. PubMed ID: 14624057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Linking the pharmacological content of ecstasy tablets to the subjective experiences of drug users.
    Brunt TM; Koeter MW; Niesink RJ; van den Brink W
    Psychopharmacology (Berl); 2012 Apr; 220(4):751-62. PubMed ID: 21993879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in illicit drug use and markets with the COVID-19 pandemic and associated restrictions: findings from the Ecstasy and Related Drugs Reporting System, 2016-20.
    Price O; Man N; Bruno R; Dietze P; Salom C; Lenton S; Grigg J; Gibbs D; Wilson T; Degenhardt L; Chan R; Thomas N; Peacock A
    Addiction; 2022 Jan; 117(1):182-194. PubMed ID: 34159666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ecstasy: as harmful as heroin?
    Scott R
    J Law Med; 2009 Dec; 17(3):327-48. PubMed ID: 20169795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Memory deficits associated with recreational use of "ecstasy" (MDMA).
    Morgan MJ
    Psychopharmacology (Berl); 1999 Jan; 141(1):30-6. PubMed ID: 9952062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. (+/-)3,4-Methylenedioxymethamphetamine ('Ecstasy')-induced serotonin neurotoxicity: studies in animals.
    Ricaurte GA; Yuan J; McCann UD
    Neuropsychobiology; 2000; 42(1):5-10. PubMed ID: 10867550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Psychopharmacology of ±3,4 Methylenedioxymethamphetamine and its Role in the Treatment of Posttraumatic Stress Disorder.
    Amoroso T
    J Psychoactive Drugs; 2015; 47(5):337-44. PubMed ID: 26579955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altered states: the clinical effects of Ecstasy.
    Cole JC; Sumnall HR
    Pharmacol Ther; 2003 Apr; 98(1):35-58. PubMed ID: 12667887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative determination of 3,4-methylenedioxymethamphetamine by thin-layer chromatography in ecstasy illicit pills in Tehran.
    Shetab Boushehri SV; Tamimi M; Kebriaeezadeh A
    Toxicol Mech Methods; 2009 Nov; 19(9):565-9. PubMed ID: 20047512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reinforcing subjective effects of (+/-) 3,4-methylenedioxymethamphetamine ("ecstasy") may be separable from its neurotoxic actions: clinical evidence.
    McCann UD; Ricaurte GA
    J Clin Psychopharmacol; 1993 Jun; 13(3):214-7. PubMed ID: 8102623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psychiatric profiles of mothers who take Ecstasy/MDMA during pregnancy: reduced depression 1 year after giving birth and quitting Ecstasy.
    Turner JJ; Parrott AC; Goodwin J; Moore DG; Fulton S; Min MO; Singer LT
    J Psychopharmacol; 2014 Jan; 28(1):55-61. PubMed ID: 24327452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective.
    Thomasius R; Zapletalova P; Petersen K; Buchert R; Andresen B; Wartberg L; Nebeling B; Schmoldt A
    J Psychopharmacol; 2006 Mar; 20(2):211-25. PubMed ID: 16510479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variability in the 3,4-methylenedioxymethamphetamine content of 'ecstasy' tablets in the UK.
    Wood DM; Stribley V; Dargan PI; Davies S; Holt DW; Ramsey J
    Emerg Med J; 2011 Sep; 28(9):764-5. PubMed ID: 20724467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rewarding effects of the optical isomers of 3,4-methylenedioxy-methylamphetamine ('Ecstasy') and 3,4-methylenedioxy-ethylamphetamine ('Eve') measured by conditioned place preference in rats.
    Meyer A; Mayerhofer A; Kovar KA; Schmidt WJ
    Neurosci Lett; 2002 Sep; 330(3):280-4. PubMed ID: 12270646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The variability of ecstasy tablets composition in Brazil.
    Togni LR; Lanaro R; Resende RR; Costa JL
    J Forensic Sci; 2015 Jan; 60(1):147-51. PubMed ID: 25125149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Depression, impulsiveness, sleep, and memory in past and present polydrug users of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy).
    Taurah L; Chandler C; Sanders G
    Psychopharmacology (Berl); 2014 Feb; 231(4):737-51. PubMed ID: 24114426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.